CompanyGraph
Sells Sensodyne, Advil, and Centrum in 170+ countries using separate government approvals in each market to keep competitors off the shelf.
- Depends onUpstream position: supplies 5 industries, depends on 0
- ScaleMarket cap is higher than 95% of all stocks globally
- FinancialsAltman Z-Score: safe zone
- Interpretations1 currently firing — 1
What this company is and how it runs — written from structure, not news.
Haleon sells Sensodyne, Advil, and Centrum across more than 170 countries, and what it really owns is not the products themselves but the separate regulatory filing in each jurisdiction that permits the exact formulation, concentration, and label claim for that market — filings that took decades to accumulate and that generic competitors cannot simply buy their way into. Because a pharmacy chain that carries all three brands draws consumer traffic across oral care, pain relief, and vitamins at once, a retailer risks losing footfall in all three aisles if it drops any one of them, which gives Haleon more negotiating weight in a single buyer conversation than any single-category rival can match. That same registration architecture cuts both ways, though: if the FDA or EMA opens a safety review on the ibuprofen in Advil or the potassium nitrate in Sensodyne, every other country's health authority runs its own parallel assessment on its own schedule, so a problem in one market can freeze the global supply of that SKU and, with it, the bundled shelf position that the other two brands depend on.
How does this company make money?
The company sells Sensodyne, Advil, and Centrum wholesale to pharmacy chains, grocery retailers, and international distributors, with the price in each case set through individual negotiations with those buyers. It also charges formulary placement fees as part of those retailer arrangements. On top of that, it sells directly to consumers through its own brand websites and through third-party platforms like Amazon.
What makes this company hard to replace?
Sensodyne, Advil, and Centrum have held premium positions on pharmacy shelves for decades, and those positions are assigned based on long track records of sales performance — a new or generic brand does not automatically get that space. Dentists name Sensodyne specifically in the instructions they give patients for sensitive teeth, so switching means going against a professional recommendation rather than just picking a different product off the shelf. Consumers who have used a specific formulation of Advil or Centrum for years would need to relearn how a different product works and what dose to take, which most people simply do not bother doing.
What limits this company?
Government health authorities like the FDA and EMA set their own review timelines, and no amount of money speeds them up. If the company wants to change the potassium nitrate concentration in Sensodyne, it has to file that change separately in each of the 170+ countries where the product is sold, then wait for each authority to finish its own review. A change that is ready to go commercially can sit blocked for months or years while those reviews run.
What does this company depend on?
The company cannot run without specialty chemical suppliers that provide active ingredients like ibuprofen and acetaminophen, FDA and EMA certification of its manufacturing facilities, placement on the shelves of retail pharmacy chains including CVS and Walgreens, product registration approvals from health authorities across 170+ countries, and trademark licenses for Advil and Centrum that trace back to the original Pfizer partnership structures.
Who depends on this company?
Retail pharmacy chains like CVS and Walgreens depend on Sensodyne and Advil as products that consumers walk in specifically asking for by name — losing those SKUs means losing that foot traffic. Dentists who recommend Sensodyne by name in patient home-care plans would lose the specific product their protocols are built around. Healthcare systems that rely on Advil and similar over-the-counter products to handle minor pain without a prescription would face pressure to cover more expensive prescription alternatives.
How does this company scale?
Once a formulation clears regulatory review in a given country, the physical work of manufacturing and packaging that product is relatively straightforward to repeat across facilities. That part scales with investment. What does not scale the same way is the approval process itself: adding a new market or changing a formulation means going back through each country's health authority on its own timeline, so the regulatory queue stays a fixed bottleneck no matter how much money the company spends.
What external forces can significantly affect this company?
Because the company buys active ingredients like ibuprofen and acetaminophen from outside suppliers and sells in 170+ countries, currency swings can push up input costs or shrink the value of overseas sales at the same time. Government policies aimed at cutting healthcare spending push consumers toward cheaper store-brand generics instead of Sensodyne, Advil, and Centrum. On the other side, aging populations in wealthier countries are increasing demand for exactly the kinds of pain management and oral care products the company sells.
Where is this company structurally vulnerable?
If the FDA or EMA opened a safety review that required changing the core ingredient in any one of the three anchor brands, that brand would have to be pulled or paused while every country ran its own assessment. The moment one brand drops out of the bundle, the company loses the multi-category negotiating weight it uses to hold premium shelf space at major pharmacy chains. Because the formulations were inherited from GSK and Pfizer rather than developed in-house, any safety finding tied to those original recipes would fall on the trademarks the company now owns — and the bundled shelf advantage that took two major corporate deals to build cannot simply be put back together.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Rising Operating Income With Low Depreciation on a Capital-Heavy Balance Sheet
Three observations describe a low-D&A profile alongside rising operating income: operating income has increased year-over-year across the trailing four years, EBIT is close to EBITDA in the most recent period (small D&A), and non-current assets are a large share of total assets. The composition is consistent with under-depreciation or a young asset base whose depreciation has not yet caught up.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.